MedTrace Logo

Hematopoietic Stem Cell Transplantation in Myeloma

NCT00415987 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2008-06-20

No results posted yet for this study

Summary

The treatment assignment is based on the presence or absence of an HLA-identical sibling donor (Genetic Randomisation, NOT formal Randomisation). Patients with suitable HLA-identical sibling donors are offered a tandem transplant approach consisting of standard autografting nonmyeloablative radiotherapy and allografting. Patients without HLA-identical siblings are treated with standard double autologous transplantation as per Institutional guidelines or enrolled in other treatment programs approved by local IRBs.This is a multi-center study. The Division of Hematology of University of Torino at the S.G.B. Hospital, Torino, Italy, is the co-ordinating Center.

Conditions

Interventions

PROCEDURE

Hematopoietic Stem Cell Transplantation

Sponsors & Collaborators

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Benedetto Bruno, MD, PhD · Divisione Ematologia, Università di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy

  • Mario Boccadoro, MD · Divisione Ematologia, Università di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2006-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00415987 on ClinicalTrials.gov